Patient P-02372
Therapy response
Stable
Tolerance
Unstable
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
96%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S14
- Day 71 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 74 GI-04 recommended — GI Support Protocol GI-04
- Day 75 Patient declined — Not now
- Day 86 ME-01 recommended — Monitoring Escalation ME-01
- Day 87 Patient accepted — Started ME-01 in the companion
- Day 90 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 71.
Primary contributors, last 14 days
- GI instability+17
- Nutritional resilience-12
- Inflammatory activity+10
- Treatment adherence+4
- Toxicity+3
What helped?
- GI Support Protocol GI-04Day 74Declined by patient
- Monitoring Escalation ME-01Day 86Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
92%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 86% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 80 and rising
- WearableSleep 5.5 h, below personal baseline
- Inflammatory signalling ↑60
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 73
- WearableHRV 33 ms, trending down
- Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 61
- Butyrate / short-chain fatty acid production ↓45
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Autonomic recovery ↓45
- WearableResting HR 80 bpm
- WearableShort sleep window
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Poor metabolizerHigher exposure at standard dose
Microbiome
Shannon diversity 2.6 · butyrate capacity 46/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 39 ms
- Sleep
- 5.8 h
- Steps
- 4,999
- Resting HR
- 76 bpm
Daily log: GI score 80, nutritional resilience 27, adherence 46.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02483 | 17% | S06 | BR-03 | no change | 64 |
| P-02025 | 31% | S15 | CR-01 | improved | 61 |
| P-02151 | 28% | S04 | CR-01 | improved | 49 |
| P-02054 | 26% | S01 | CR-01 | improved | 57 |
| P-02009 | 25% | S08 | CR-01 | improved | 64 |
| P-02154 | 24% | S16 | CR-01 | improved | 57 |
| P-02233 | 22% | S16 | CR-01 | improved | 66 |
| P-02395 | 17% | S12 | DT-01 | improved | 57 |
| P-02491 | 17% | S09 | DT-01 | no change | 65 |
| P-02274 | 16% | S15 | DT-01 | improved | 50 |
| P-02339 | 16% | S03 | DT-01 | improved | 50 |
| P-02348 | 43% | S14 | GI-04 | improved | 49 |